CA3187516A1 - Polycyclic cap-dependent endonuclease inhibitors for treating or preventing influenza - Google Patents
Polycyclic cap-dependent endonuclease inhibitors for treating or preventing influenzaInfo
- Publication number
- CA3187516A1 CA3187516A1 CA3187516A CA3187516A CA3187516A1 CA 3187516 A1 CA3187516 A1 CA 3187516A1 CA 3187516 A CA3187516 A CA 3187516A CA 3187516 A CA3187516 A CA 3187516A CA 3187516 A1 CA3187516 A1 CA 3187516A1
- Authority
- CA
- Canada
- Prior art keywords
- int
- mmol
- compound
- peak
- sfc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063056861P | 2020-07-27 | 2020-07-27 | |
| US63/056,861 | 2020-07-27 | ||
| PCT/US2021/042711 WO2022026285A1 (en) | 2020-07-27 | 2021-07-22 | Polycyclic cap-dependent endonuclease inhibitors for treating or preventing influenza |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3187516A1 true CA3187516A1 (en) | 2022-02-03 |
Family
ID=80038102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3187516A Pending CA3187516A1 (en) | 2020-07-27 | 2021-07-22 | Polycyclic cap-dependent endonuclease inhibitors for treating or preventing influenza |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240018145A1 (https=) |
| EP (1) | EP4188379B1 (https=) |
| JP (1) | JP7695339B2 (https=) |
| KR (1) | KR20230044252A (https=) |
| CN (1) | CN116490190A (https=) |
| AU (1) | AU2021315475A1 (https=) |
| BR (1) | BR112023001325A2 (https=) |
| CA (1) | CA3187516A1 (https=) |
| MX (1) | MX2023001194A (https=) |
| WO (1) | WO2022026285A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118804908A (zh) * | 2022-03-01 | 2024-10-18 | 弗门尼舍有限公司 | 制备γ,δ-不饱和醛衍生物的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5475109A (en) * | 1994-10-17 | 1995-12-12 | Merck & Co., Inc. | Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease |
| EA200801144A1 (ru) | 2005-10-27 | 2008-10-30 | Сионоги Энд Ко., Лтд. | Полициклическое карбамоилпиридоновое производное, обладающее ингибиторной активностью в отношении интегразы вич |
| MX2013003139A (es) | 2010-09-24 | 2013-06-18 | Shionogi & Co | Profarmaco de derivado de carbamoilpiridona policiclica substituida. |
| TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| EP4257137A3 (en) * | 2018-05-31 | 2023-11-01 | Shionogi & Co., Ltd | Polycyclic carbamoylpyridone derivatives for the treatment of hiv |
| AU2019277547B2 (en) | 2018-05-31 | 2024-10-10 | Shionogi & Co., Ltd. | Polycyclic pyridone derivative |
| CN113286793B (zh) | 2018-09-10 | 2024-04-05 | 共结晶制药公司 | 吡咯并吡嗪和吡啶并三嗪类流感病毒复制抑制剂 |
-
2021
- 2021-07-22 KR KR1020237006229A patent/KR20230044252A/ko active Pending
- 2021-07-22 EP EP21848925.0A patent/EP4188379B1/en active Active
- 2021-07-22 CA CA3187516A patent/CA3187516A1/en active Pending
- 2021-07-22 JP JP2023505421A patent/JP7695339B2/ja active Active
- 2021-07-22 CN CN202180065598.0A patent/CN116490190A/zh active Pending
- 2021-07-22 BR BR112023001325A patent/BR112023001325A2/pt unknown
- 2021-07-22 US US18/015,465 patent/US20240018145A1/en active Pending
- 2021-07-22 MX MX2023001194A patent/MX2023001194A/es unknown
- 2021-07-22 AU AU2021315475A patent/AU2021315475A1/en active Pending
- 2021-07-22 WO PCT/US2021/042711 patent/WO2022026285A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN116490190A (zh) | 2023-07-25 |
| KR20230044252A (ko) | 2023-04-03 |
| EP4188379B1 (en) | 2026-02-25 |
| US20240018145A1 (en) | 2024-01-18 |
| JP7695339B2 (ja) | 2025-06-18 |
| EP4188379A4 (en) | 2024-08-28 |
| MX2023001194A (es) | 2023-04-20 |
| EP4188379A1 (en) | 2023-06-07 |
| BR112023001325A2 (pt) | 2023-02-14 |
| AU2021315475A1 (en) | 2023-03-02 |
| WO2022026285A1 (en) | 2022-02-03 |
| AU2021315475A8 (en) | 2023-04-06 |
| JP2023535771A (ja) | 2023-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3053484T3 (en) | Cyclopropyl dihydroquinoline sulfonamide compounds | |
| JP2024514990A (ja) | ヘテロアルキルジヒドロキノリンスルホンアミド化合物 | |
| US7968564B2 (en) | HIV integrase inhibitors | |
| CA3124317A1 (en) | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections | |
| MX2013008419A (es) | Inhibidores del virus de la hepatitis c. | |
| JP2023533915A (ja) | Ｈｉｖの治療のためのカプシド阻害剤 | |
| CN113227093A (zh) | 结晶螺环化合物、包含该化合物的剂型、用于疾病治疗的方法和再结晶方法 | |
| CN101389628A (zh) | 作为eg5驱动蛋白调节剂的吲哚并吡啶 | |
| JP2021503443A (ja) | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト | |
| WO2021060453A1 (ja) | 架橋型光学活性２級アミン誘導体 | |
| CA3187516A1 (en) | Polycyclic cap-dependent endonuclease inhibitors for treating or preventing influenza | |
| CA3178647A1 (en) | Substituted tricyclic amides, analogues thereof, and methods using same | |
| EP4649086A1 (en) | Protease inhibitors for treating or preventing coronavirus infection | |
| RU2841261C1 (ru) | Полициклические ингибиторы кэп-зависимой эндонуклеазы для лечения или профилактики гриппа | |
| ZA200602443B (en) | Aryloxy and arylalkyleneoxy substituted imidazoquinolines | |
| HK40058222A (en) | A crystalline spirocyclic compound, a dosage form containing, a method for using in treatment of disease, and a method for recrystallizing | |
| WO2023018913A1 (en) | Polycyclic cap-dependent endonuclease inhibitors for treating or preventing influenza | |
| TW202545941A (zh) | 用於緩解疼痛之nav1.8鈉通道之小分子抑制劑 | |
| WO2005051385A1 (en) | Substituted heterocycles useful for treating hcv infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250616 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250616 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250717 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250717 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250925 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250925 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250925 |